Golden
Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company.

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

Funding rounds

Funding round
Funding round amount (USD)
Funding type
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn







Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









News

Title
Author
Date
Publisher
Description
December 10, 2018
WebWire
Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces today a Settlement and License Agreement with Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY). Alnylam will license patents from Silence and will pay Silence a tiered royalty on net sales of ONPATTROTMin the EU only ranging from 0.33 percent to 1.0 percent through 2023. All legal proceedings in all jurisd...